Loading...
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
The multikinase inhibitor sorafenib is under clinical investigation for the treatment of many solid tumors, but in most cases, the molecular target responsible for the clinical effect is unknown. Furthermore, enhancing the effectiveness of sorafenib using combination strategies is a major clinical c...
Na minha lista:
Udgivet i: | Int J Cancer |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
Blackwell Publishing Ltd
2015
|
Fag: | |
Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4312923/ https://ncbi.nlm.nih.gov/pubmed/25080865 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.29113 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|